Allele Frequency–Adjusted Blood-Based Tumor Mutational Burden As a Predictor of Overall Survival for Patients with NSCLC Treated with PD-(L)1 Inhibitors
Zhijie Wang,Jianchun Duan,Guoqiang Wang,Jing Zhao,Jiachen Xu,Jiefei Han,Zhengyi Zhao,Jun Zhao,Bo Zhu,Minglei Zhuo,Jianguo Sun,Hua Bai,Rui Wan,Xin Wang,Kailun Fei,Shuhang Wang,Xiaochen Zhao,Yuzi Zhang,Mengli Huang,Depei Huang,Chuang Qi,Chan Gao,Yuezong Bai,Hua Dong,Lei Xiong,Yanhua Tian,Di Wang,Chunwei Xu,Wenxian Wang,Junling Li,Xingsheng Hu,Shangli Cai,Jie Wang
DOI: https://doi.org/10.1016/j.jtho.2019.12.001
IF: 20.121
2020-01-01
Journal of Thoracic Oncology
Abstract:Introduction: Blood-based tumor mutational burden (bTMB) has been studied to identify patients with NSCLC who would benefit from anti-programmed cell death protein 1 (anti-PD-1) or anti-programmed death ligand 1 (anti-PD-L1) therapies. However, it failed to predict overall survival (OS) benefits, which warrants further exploration. Methods: Three independent cohorts of patients with NSCLC treated with immunotherapy were used in this study. A new bTMB algorithm was first developed in the two independent cohorts (POPLAR, N = 211, and OAK, N = 462) and further validated in the third National Cancer Center (NCC) cohort (N = 64). Results: bTMB-H (bTMB >= cutoff point) was not associated with favorable OS after immunotherapy regardless of the cutoff points in either the POPLAR and OAK or the NCC cohorts (p > 0.05) owing to its correlation with the amount of circulating tumor DNA, which was associated with poor OS. In the POPLAR and OAK cohorts, with allele frequency (AF) adjustment, a high AF bTMB (HAF-bTMB, mutation counts with an AF > 5%) was strongly correlated with the amount of circulating tumor DNA (Pearson r = 0.65), whereas a low AF bTMB (LAF-bTMB, mutation counts with an AF <= 5%) was not (Pearson r = 0.09). LAF-bTMB-H was associated with favorable OS (hazard ratio [HR] = 0.70, 95% confidence interval [CI]: 0.52-0.95, p = 0.02), progression-free survival (PFS; HR = 0.62, 95% CI: 0.47-0.80, p < 0.001), and objective response rate (ORR) (p < 0.001) after immunotherapy but not chemotherapy, with a cutoff point of 12 trained in the POPLAR cohort and validated in the OAK cohort. The LAF-bTMB algorithm was further validated in the NCC cohort in which LAF-bTMB-H was associated with OS (HR = 0.20, 95% CI: 0.05-0.84, p = 0.02), PFS (HR = 0.30, 95% CI: 0.13-0.70, p = 0.003), and ORR (p = 0.001). Conclusions: We developed and validated a new LAF-bTMB algorithm as a feasible predictor of OS, PFS, and ORR after anti-PD-(L)1 therapies in patients with NSCLC, which needs to be prospectively validated. (C) 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.